Company intelligence / Profile preview

CoviCept Therapeutics

Rancho Santa Fe, California, USApitchbook.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CoviCept Therapeutics develops small-molecule antivirals targeting host proteins essential for the replication of RNA viruses. Their lead candidate has demonstrated efficacy against SARS-CoV‑2 and other RNA viruses in preclinical models and has shown good bioavailability and safety in humans. The company initiated a Phase 2 clinical trial with its oral antiviral PJS‑539 for COVID‑19 patients as of late 2021. The approach aims to provide a stockpiled therapeutic option with low risk of resistance due to its host-targeted mechanism.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

PJS-539

Unknown

Partnerships

Forbion Capital Partners (lead investor and operational support partner)

Beyond the preview

Go deeper on CoviCept Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoviCept Therapeutics.

Explore the full profile